To main content

Projects

Filter on
252 hits

OntoCommons - Ontology Commons Ecosystem Toolkit

Start: 2020
End: 2023

OntoCommons is an H2020 CSA project dedicated to the standardisation of data documentation across all domains related to materials and manufacturing.

VirtuOSA - Virtual Surgery in the Upper Airways – New Solutions to Obstructive Sleep Apnea Treatment

Start: 2020
End: 2024

The current project aims at enabling key technology for patient-specific diagnostics and treatment of Obstructive Sleep Apnea (OSA). When evaluating treatment options, clinicians are currently relying on general guidelines and personal experience, but they are lacking objective and predictive decision support tools. This project will provide required insight and software tools for computer-aided diagnostics and treatment of OSA through the promotion of Virtual surgery. Thereby, OSA patients can be treated more targeted, with reduced risk for the patient and reduced cost for society.

In-No-Plastic: Innovative approaches towards prevention, removal and reuse of marine plastic litter

Start: 2020
End: 2024

In-No-Plastic’s goal is to develop and demonstrate nano-, micro, and macro-plastic clean-up technologies in the aquatic ecosystems.

BIG-MAP: Battery Interface Genome – Materials Acceleration Platform

Start: 01/09/2020
End: 31/08/2023

Batteries play an important role in our daily lives, powering smart phones, computers, and cars. As the world races to reduce CO2 emissions, the development of sustainable and high-performance batteries takes on an even more important role enabling the large-scale storage of renewable energy, electric shipping, and even electric aviation. The BIG-MAP (Battery Interface Genome – Materials Acceleration Platform) project will accelerate the speed of battery development by fundamentally changing the way we invent batteries.

CleanExport

Start: 2020
End: 2024

Norway's position as an energy-exporting country is changing due to decarbonization of the European energy market. To fulfil the Paris Agreement, CO2 emissions must be reduced in all parts of the energy value chain from generation to end-use. There is a surge to replace fossil-fuelled energy generation with carbon-free alternatives and renewable generation, and a need to ramp up deployment of CO2 capture and storage (CCS). This ongoing transition of the energy system creates both opportunities and challenges for the utilization of Norway's fossil energy and renewable electric power resources.

Efficient CO2 capture from waste-derived solid fuels using CLC technology - CLC-SRF

Start: 2020
End: 2022

CO2 emissions from conversion of waste-derived fuels are estimated to about 18 million tonnes per year (ERFO - European Recovered Fuel Organisation, 2015). The report further estimates the market to increase, to CO2 emissions equivalent to more than 60 million tonnes per year. It is evident that capture of this CO2 should be considered.

Mucoprotect – A novel generic system for targeted delivery of oral vaccines

Start: 2020
End: 2022

Vaccines are by far the most important tool in preventing disease in Norwegian aquaculture. Without the systematic use of efficient vaccines industrialisied fish farming would be an impossibility. Despite this, 53 million salmon were lost in Norway in 2017 due to illness and injury, also related to salmon lice treatment. In the project we will develop novel, clever vaccines based on nanoparticles, tailored for oral vaccination.

SIP GUT: Development of tools for gut microbiota research

Start: 2020
End: 2023

The gut microbiota are the microorganisms that live in the gastrointestinal tract. They play a fundamental role in health and disease of the host. Detailed understanding of gut microbiota–host interactions is therefore of great importance as this may be used to find new treatments to various diseases and increase the well-being of humans and animals.

TrippelTarg - Triple Targeting of Biodegradable Nanoparticles for Treatment of Cancer

Start: 2020
End: 2020

SINTEF want to further develop a targeted treatment strategy that has shown promising effects in animals with patient-derived tumors. The strategy is based on the use of nanoparticles developed by SINTEF containing a cytostatic drug.
Neste side